|
Ensce Biosciences, Inc. (ENSC) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Ensysce Biosciences, Inc. (ENSC) Bundle
¡Simplifique la valoración de Ensysce Biosciences, Inc. (ENSC) con esta calculadora DCF personalizable! Con Real Ensysce Biosciences, Inc. (ENSC) financieros y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Ensysce Biosciences, Inc. (ENSC) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.8 | 3.9 | 3.5 | 2.5 | 2.2 | 2.5 | 2.8 | 3.2 | 3.6 | 4.0 |
| Revenue Growth, % | 0 | 122.86 | -10.18 | -28.54 | -11.61 | 12.42 | 12.42 | 12.42 | 12.42 | 12.42 |
| EBITDA | .9 | -1.6 | -19.9 | -24.2 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| EBITDA, % | 52.22 | -41.03 | -562.71 | -959.91 | -480.52 | -57.76 | -57.76 | -57.76 | -57.76 | -57.76 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.01139481 | 0.00511293 | 0.00427617 | 0.00598403 | 0 | 0.00535359 | 0.00535359 | 0.00535359 | 0.00535359 | 0.00535359 |
| EBIT | .9 | -1.6 | -19.9 | -24.2 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| EBIT, % | 52.21 | -41.04 | -562.71 | -959.91 | -480.52 | -57.77 | -57.77 | -57.77 | -57.77 | -57.77 |
| Total Cash | 1.1 | .2 | 12.3 | 3.1 | 1.1 | 1.6 | 1.8 | 2.0 | 2.2 | 2.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .4 | .3 | .1 | .1 | .2 | .2 | .2 | .2 |
| Account Receivables, % | 0 | 0 | 12.51 | 10.97 | 4.37 | 5.57 | 5.57 | 5.57 | 5.57 | 5.57 |
| Inventories | .0 | .0 | -.4 | -.3 | .0 | -.1 | -.1 | -.1 | -.2 | -.2 |
| Inventories, % | 0.000056690596 | 0 | -12.51 | -10.97 | 0 | -4.7 | -4.7 | -4.7 | -4.7 | -4.7 |
| Accounts Payable | .5 | 1.7 | .3 | 2.9 | 1.9 | 1.4 | 1.5 | 1.7 | 1.9 | 2.2 |
| Accounts Payable, % | 30.66 | 43.87 | 8.53 | 116.66 | 86.8 | 53.97 | 53.97 | 53.97 | 53.97 | 53.97 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 0 | 0 | 0 | 0.00008966519 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 |
| EBITAT | 1.5 | -9.4 | -19.9 | -25.0 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.0 | -8.2 | -21.3 | -22.3 | -11.8 | -2.0 | -1.5 | -1.6 | -1.8 | -2.1 |
| WACC, % | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -31 | |||||||||
| Present Terminal Value | -20 | |||||||||
| Enterprise Value | -27 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -27 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -11.91 |
What You Will Get
- Pre-Filled Financial Model: Ensysce Biosciences, Inc.’s (ENSC) actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to Ensysce.
- Instant Calculations: Automatic updates ensure you see results as you make changes to your forecasts.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of Ensysce Biosciences.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts on Ensysce.
Key Features
- Innovative Drug Development Platform: Leverages advanced technologies for developing pain management solutions.
- Robust Clinical Trial Management: Streamlined processes for efficient planning and execution of clinical trials.
- Customizable Research Models: Tailor research parameters to optimize drug efficacy and safety assessments.
- Integrated Financial Metrics: Evaluate key performance indicators to gauge financial health and growth potential for Ensysce Biosciences.
- Dynamic Reporting Tools: Visual presentations of research outcomes and financial data for informed decision-making.
How It Works
- 1. Access the Template: Download and open the Excel file containing Ensysce Biosciences, Inc. (ENSC) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures relevant to Ensysce.
- 3. View Results Instantly: The DCF model automatically computes the intrinsic value and NPV for Ensysce Biosciences.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation possibilities for ENSC.
- 5. Present with Assurance: Deliver professional valuation insights to bolster your investment decisions regarding Ensysce Biosciences, Inc. (ENSC).
Why Choose Ensysce Biosciences, Inc. (ENSC)?
- Innovative Solutions: Cutting-edge technology designed to enhance drug delivery systems.
- Proven Expertise: Backed by a team of experienced professionals in the biotech field.
- Commitment to Safety: Focused on developing products that prioritize patient safety and efficacy.
- Robust Research: Extensive clinical trials support the reliability and effectiveness of our solutions.
- Industry Recognition: A trusted name in biosciences, known for quality and innovation.
Who Should Use This Product?
- Investors: Accurately assess Ensysce Biosciences, Inc.'s (ENSC) fair value prior to making investment choices.
- CFOs: Utilize a top-tier DCF model for financial analysis and reporting.
- Consultants: Seamlessly modify the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices of leading biotech firms.
- Educators: Employ it as a resource to illustrate valuation techniques in the classroom.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Ensysce Biosciences, Inc. (ENSC).
- Real-World Data: Ensysce’s historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results specific to Ensysce Biosciences, Inc. (ENSC).